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Abstract
Background: Systemic Lupus Erythematosus (SLE) is characterised by fluctuating periods of minimal disease activity
and ‘flare’. Flare is an important outcome variable impacting the disease burden associated with SLE. The objective
of this study was to obtain population-based utility values for varying severities of flare to measure the impact on
health-related quality of life (HRQoL) in Australia, Canada, France, Japan, Spain and the UK.
Methods: Six health states (HS) for varying severities of flare were developed based on literature, patient blogs, and
interviews with patients (n = 12), rheumatologists (n = 7) and nurses (n = 2). HS were validated by independent clinical
experts (n = 6) and pilot interviews (n = 10, UK). HS were evaluated using the time-trade-off (TTO) method during
face-to-face interviews with a minimum representative sample (n = 100) of the general population, per-country. Visual
Analog Scale (VAS) scores were obtained to validate TTO scores. TTO scores were converted into utility values.
Results: The highest mean TTO utility scores were observed for the anchor HS (minimal disease activity) across all
countries; means ranged from 0.66 in Japan to 0.82 in UK. All flare HS were associated with a disutility compared with the
anchor HS (p < 0.001), means ranged across countries: mild flare HS: 0.55–0.71, moderate flare HS: 0.38–0.53, severe renal
flare HS: 0.33–0.45, severe central nervous system (CNS) flare HS: 0.30–0.45 and severe generalised flare HS: 0.19–0.33.
Mean VAS scores followed the same trend.
Conclusions: These results show increasing severity of flare has a detrimental impact on HRQoL. The severe generalised
flare HS received the lowest mean utility score suggesting that the perceived day-to-day impact of a severe generalised
flare was greater than a severe CNS or severe renal flare. This is, to the best of our knowledge, the first utility study to
assess varying severities of flare in SLE across six different countries.
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Background
Systemic Lupus Erythematosus (SLE) is a chronic, multi-
system, autoimmune disease which predominantly affects
women (>90 %) [1]. SLE is associated with the inflamma-
tion and subsequent damage of multiple organ systems,
notably the skin, joints, heart, lungs, kidneys and central
nervous system (CNS) [1]. The manifestations of SLE are
wide-ranging, including but not limited to rashes
(predominantly on sun exposed areas), photosensitiv-
ity, polyarthritis, ulcers and fatigue [1]. SLE patients
typically experience multiple manifestations [1].
SLE is characterised by periods of fluctuating disease ac-
tivity, a patient can experience periods of minimal disease
activity and periods of ‘flare’ [1]. Changes in disease activ-
ity are captured using validated indices such as British Isle
Lupus Activity Group (BILAG) index [2, 3] and Safety of
Estrogens in Lupus Erythematosus National Assessment
version of the Systemic Lupus Erythematosus Disease
Activity Index (SELENA-SLEDAI) [3, 4]. Severe flares are
associated with organ damage accrual and mortality [3].
Management of SLE is increasingly aimed at the mini-
misation of disease activity or treatment-related adverse
events which may contribute to irreversible organ damage
and an increase in co-morbidities [5, 6, 7].* Correspondence: Jennifer.cook@adelphivalues.com
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Flare has been shown to be an important outcome vari-
able impacting the burden of disease associated with SLE,
including patient-reported health-related quality of life
(HRQoL) and economic burden. Major organ flares such
as those involving the kidneys or CNS are associated with
increased healthcare resource use, including hospital
admissions and procedures [7, 8]. The clinical burden of
severe renal flares is substantial however, previous studies
have demonstrated no significant difference in HRQoL
between patients with and without renal involvement [9].
Previous studies have shown musculoskeletal flares
and subsequently joint pain are a significant predictor of
low HRQoL in SLE patients [10, 11]. Patients experien-
cing high levels of pain were also burdened with greater
fatigue, anxiety and depression, than SLE patients ex-
periencing low levels of pain [12]. Fatigue, anxiety and
depression are associated with a detrimental impact on
patient HRQoL [12–14].
Health utilities play an important role in health eco-
nomic evaluations and provide a method of assessing
the impact of SLE flare on HRQoL. Health utilities are
values that define an individual’s preference for a specific
health outcome, and are used alongside clinical out-
comes to define quality-adjusted life years (QALYs) in
health economic evaluations.
Reimbursement bodies recommend indirect elicitation of
utilities using the EQ-5D, however when this instrument is
deemed insufficient direct valuation techniques can be used
[15–18]. There are a number of alternative direct valuation
techniques. The Time Trade Off (TTO) method, adminis-
tered via face-to-face interviews with the general public is
the preferred valuation technique by the National Institute
for Health and Care Excellence (NICE), when the EQ-5D is
not suitable [18].
The objective of this study was to obtain population-
based utility values for varying severities of SLE flare to
measure the impact on HRQoL for Australia (AU), Canada
(CA), France (FR), Japan (JPN), Spain (ES) and the United
Kingdom (UK). This is, to the best of our knowledge, the
first utility study to assess varying severities of flare in SLE
across six different countries.
Methods
Study design and rationale
A cross-sectional study, using the TTO method, was con-
ducted with a minimum of 100 members of the general
public in AU, CA, ES, FR, JPN and the UK [19]. EQ-5D
data collected within randomised controlled trials may not
optimally capture the disutility associated with SLE flares
[20] when administered at set time points which may not
have coincided with a patient experiencing a flare. In
addition the EQ-5D may fail to capture the anxiety experi-
enced between flares or adverse events associated with
treatment [20]. Therefore direct elicitation was considered
an appropriate tool for elicitation of utility values. The
TTO method was considered to be the most appropriate
direct elicitation technique versus standard gamble (SG).
SG is associated with numeracy issues and risk aversion
when asking the participant to “bet” on death [21]. Of sig-
nificance to this study, SG has been shown to be less re-
sponsive to musculoskeletal pain [21]. An overview of the
overall study methodology is presented in Fig 1.
Development of health states
Six HS for varying severities of flare were developed based
on published literature relating to HRQoL in patients with
SLE, patient blogs, interviews with patients (n = 12) and in-
terviews with a group of clinical experts (rheumatologists
(n = 7) and nurses (n = 2)).
A recruitment agency was used to recruit patients in the
UK (n = 7) and JPN (n = 5); a patient screener was used to
determine eligibility for the study. Patients from the UK
and JPN were recruited due to potential differences in dis-
ease perception and management across countries, as the
greatest degree of cultural disparity was expected between
these two populations. To ensure accurate recall of experi-
ence of symptoms and impacts during a flare, all patients
had to have had one or more flares within the past
12 months and have consulted with their doctor regarding
the flare(s). Semi-structured telephone interviews with pa-
tients provided insights into the symptoms associated with
varying severities of flare and the impact of flare on
patients’ HRQoL. A selection of quotes from the patient
interviews are presented in Table 1. Semi-structured tele-
phone interviews with clinical experts provided additional
insight into the symptoms associated with different organ
manifestations and varying severities of flare.
The HS aimed to provide a simple and informative de-
scription of flare and reflected the experience of a hypo-
thetical SLE patient, aged 41 years (based on mean age
of SLE patients in published studies) [1, 3, 6, 22]. Given
the heterogeneous nature of SLE, the number of HS
needed to represent different organ manifestations (see
Table 2) across varying severities of flare and had to be bal-
anced with other factors such as unnecessary complexity
and respondent fatigue. To capture increasing severities of
flare, six HS were developed including three separate HS
for severe flare (severe generalised flare, severe renal flare,
severe CNS flare). HS were based on the EQ-5D descriptive
system of mobility, self-care, pain, usual activities and emo-
tional elements (see Table 1).
The HS descriptions were verified for accuracy, valid-
ity and cultural relevance by an independent expert
group of Rheumatologists (n = 6).
Utility elicitation process
Utility values were elicited via face-to-face interviews
using the TTO method with members of the general
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public in each country. Valuation of the HS by the gen-
eral public are recommended as resource allocation in a
publically funded healthcare system should be weighted
by the general public’s perception of disease burden [18].
The HS descriptions were piloted with 10 members of the
general public to assess comprehensiveness. The outcome
of the pilot study resulted in minor wording changes to
the HS descriptions.
Based on other population studies, utilities were elic-
tated from a minimum of 100 people from the general
population, for each country to achieve a representative
cross-section of society [23]. Geographic and demograph-
ically representative samples based on general population
statistics were recruited, except for Japan where the Tokyo
population was deemed to be representative for utility
elicitation (see Table 3). Participants were recruited using
a population screener, to ensure demographic quotas were
met. Demographic data collected in each country in-
cluded; gender, age, marital status, education, employment
status and income. All interviews were audio recorded;
participants provided written consent and were given rea-
sonable compensation for their time (equivalent to £30
across the six countries).
Two exercises were completed during the interviews.
The Visual Analogue Scale (VAS) exercise was com-
pleted as a warm-up to familiarise participants with
the HS. The VAS is a scale ranging from 0 to 100
where 0 represents death and 100 represents best
imaginable health. Each HS was read out in full to the
participant by the interviewer, the participant was
asked to rate the HS on the scale of 0 to 100. The par-
ticipant was also asked to rate their own health at that
moment in time on the VAS scale. Own health scores
could be used to explore any inconsistencies in VAS or
utility scores if required as own health can impact the
evaluation of HS [18]. The TTO exercise used a hori-
zontal scale representing 1–10 years in ‘full health’. A
hypothetical example was used to explain the TTO
concept of trading time to live in a preferential state.
Each HS was read to the participant; the participant
was then asked to state their preference for 10 years in
the HS followed by death or 10 years in ‘full health’
followed by death. A ‘flip-flop/ping-pong’ technique
was used, where the participant was offered more or
less time in ‘full health’ versus 10 years in the HS until
a point of indifference was reached. Trading was further
refined into months, weeks and days.
Data analysis
The TTO scores were recorded as number of years,
months and days (≤10 years) for each HS. The scores
were decimalised and divided by 10 to give a final utility
score between 0 and 1 (e.g. utility score for 5 years
6 months = 5.5/10 = 0.55). A minimum utility score of 0
Fig. 1 Overview of study methodology
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Table 1 A sample of patient quotes used to inform the development of the health states and a brief description of the symptoms
and impacts included in each health state
Health state Symptoms Brief description of impact Patient quotes
Anchor Mild joint pain Mild joint pain, minimal impact on
mobility
“It’s frustrating, people don’t think you are ill”
Sensitive skin Sensitive skin may impact usual activities
as
must minimise exposure to the sun
Mild fatigue Fatigue may impact usual activities i.e.
change
plans with friends
“If I do something [go out, exercise], I know everything




Moderate joint pain, unable to walk long
distances, some difficulty with dexterity
e.g. opening jars





Self-conscious of rash and hair loss “I can’t walk for more than 45minutes- I get too tired”






Severe joint pain, difficulty standing and
walking
i.e. require aid getting in and out of the
shower






Pain when eating “pain from head to toe, every bone”
Chest pain disturbs sleep
Mouth ulcers Fatigue may impact on usual activities i.e.
take time off work
“Someone has taken your body and replaced it with an old body”
Chest pain Frequent blood and urine tests required
Severe fatigue Medication is increased causing weight
gain and nausea
Hematological Feeling anxious and depressed
Severe
generalised
Joint pain is all
over
Very severe joint pain, impossible to
get comfortable






Eating and swallowing is unbearably
painful
“[You feel like] is this ever going to end”
Mouth ulcers Finger ulcers are painful and must be
dressed
regularly by a nurse







Severe fatigue impacts usual activities i.e.
stay
in bed all day, require carrying to the
toilet
Severe fatigue Admission to hospital for several days
Hematological Frequent blood and urine tests required
Medication is increased causing weight
gain
and nausea
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is where a participant rated the HS comparable to death
and a maximum utility score of 1 is where the partici-
pant was unwilling to trade any time.
A minimum of 40 % of the audio recordings and the
documented VAS and TTO scores from each country
were quality checked by an independent analyst. In
addition a minimum of 20 % of the score sheets were then
cross compared against data input tables for each country,
used for statistical programming, by an independent
analyst. No participants were excluded from the analysis.
Given that this study recruited a representative proportion
of the general population in each country all responses
were included to provide the most comprehensive societal
perspective.
All scores were inputted into Microsoft Excel (version
2010), data were exported and analyses were performed
using SAS (version 9.3). Descriptive analyses including
mean, median, interquartile range, minimum, maximum
Table 1 A sample of patient quotes used to inform the development of the health states and a brief description of the symptoms
and impacts included in each health state (Continued)
Long-term monitoring for diabetes, heart
attack,
stroke and fractures
Signed-off work for weeks
Feeling anxious and depressed
Severe CNS Memory loss Feeling disorientated and confused “It feels like my brain has gone through a cheese grater, I can’t speak, I
can’t concentrate, I get confused”
Blurred vision Admission to hospital for several days “People think you are stupid”
Seizures Investigative procedures including
neurological
tests and MRI scans
Plus the
symptoms
Medication is increased causing weight
gain
and nausea
outlined for the Seizures may impact on usual activities
i.e. being unable to drive
mild HS Loss of independence
Possibility of permanent mental damage
Signed-off work for weeks
Plus the impacts outlined for the mild HS
Severe Renal Swollen legs Admission to hospital for several days “I have to work around hospital appointments, work
are accommodating- I don’t know how long this will last”
Severe headache Require a kidney biopsy
Signs of kidney
dysfunction






Return to hospital monthly for more tests
Possibility of kidney failure and dialysis
Signed-off work for weeks
Plus the impacts outlined for the mild HS
CNS- Central nervous system, HS-Health state
Table 2 Summary of organ manifestations included within each health state
Health state Organ manifestation
Skin Joints Hematological Heart or Lungs Renal CNS
Anchor √ √
Mild √ √
Moderate √ √ √ √
Severe generalised √ √ √ √
Severe CNS √ √ √
Severe renal √ √ √
CNS- Central nervous system, HS-Health state
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and standard deviation of the VAS and TTO scores were
derived. Paired, two-tailed t-tests were performed at the
5 % level on the VAS scores and TTO utility scores to
test for significant differences between all HS combina-
tions. No multiplicity adjustments were conducted.
Ethics
The study investigators reviewed publically available
guidance within each country to determine if ethics
approval was required for utility elicitation interviews.
The relevant research ethics services in AU, CAN, ES,
FR, UK confirmed that ethics approval was not required.
Ethics approval was submitted for the study in Japan;
approval was granted November 2013.
Results
Study population
In total 619 interviews were conducted across six coun-
tries, there were no instances of participants refusing to
complete the TTO exercise; scores were recorded for all
participants. The demographic split of participants across
countries by gender and age is presented in Table 3.
Utility results
The highest mean TTO utility scores were observed for
the anchor HS (minimal disease activity); means ranged
from 0.66 in JPN to 0.82 in UK. All flare HS were asso-
ciated with a disutility compared with the anchor HS
(p < 0.001) in all six countries: mean mild flare HS
ranged from 0.55 in JPN to 0.71 in ES and UK, mean
moderate flare HS ranged from 0.38 in JPN to 0.53 in ES,
mean severe renal HS ranged from 0.33 in FR to 0.45 in
UK, mean severe CNS flare HS ranged from 0.30 in AU to
0.45 in ES and mean severe generalised flare HS ranged
from 0.19 in JPN to 0.33 in ES. Within countries a wide
range of scores were recorded by participants as indicated
by the minimum and maximum TTO utility scores.
Descriptive statistics for each HS by country are provided
in Table 4.
There was no signal of the data not being normally
distributed, the means were close to their corresponding
medians (the highest difference is 0.1 for the anchor HS
collected in Spain) and all SD were consistent across
countries and HS (ranging from 0.18 to 0.30).
The lowest mean utility score recorded across all
countries was for the severe generalised HS. Paired t-tests
demonstrated a statistically significant difference between
the utility scores for the mild, moderate and severe gener-
alised HS (p < 0.001), across all countries, which suggests
the perception of increasing severity of these HS is
consistent across countries.
The mean scores for severe CNS flare and severe renal
flare HS were consistently higher than the severe general-
ised flare HS. Paired t-tests demonstrated a statistically sig-
nificant difference between the utility scores for the severe
generalised HS and the CNS flare HS or severe renal flare
HS (p > 0.005), across all countries. In the UK and Japan
no statistically significant difference was observed between
the moderate HS and the renal HS (p > 0.1). Therefore the
perceived day to day impact of a severe generalised flare is
greater than severe CNS or severe renal flare.
The VAS scores were used to validate the TTO scores.
The general trend of the data across all countries suggests
both the TTO utility and VAS scores decreased from the
anchor health state to the severe generalised health state
i.e. with increasing flare severity. The mean VAS score for
own health was higher than the anchor HS (84.96 versus
62.91); suggesting SLE without flare also has a detrimental
impact on HRQoL.
Discussion
The objective of this study was to elicit six utility values
associated with increasing severity of flare. A decrease in
utility was observed with increasing severity of flare.
These data suggest, based on valuation by the general
population, that flares of any severity are seen to have a
disutility over the anchor HS (minimal disease activity).
Table 3 Participant demographics across countries*
Participant characteristics AU (n = 100) CA (n = 108) ES (n = 100) FR (n = 100) JPN (n = 101) UK (n = 110)
Gender Male 46 (46 %) 53 (49.07 %) 50 (50 %) 50 (50 %) 55 (54.46 %) 56 (50.91 %)
Female 54 (54 %) 55 (50.93 %) 50 (50 %) 50 (50 %) 46 (45.54 %) 54 (49.10 %)
Age (years) <18 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
18–20 7 (7 %) 13 (12.04 %) 7 (7 %) 10 (10 %) 5 (4.95 %) 10 (9.10 %)
21–30 27 (27 %) 21 (19.44 %) 15 (15 %) 17 (17 %) 15 (14.85 %) 22 (20 %)
31–40 23 (23 %) 17 (15.74 %) 15 (15 %) 19 (19 %) 18 (17.82 %) 22 (20 %)
41–50 16 (16 %) 17 (15.74 %) 27 (27 %) 16 (16 %) 16 (15.84 %) 18 (16.36 %)
51–60 13 (13 %) 21 (19.44 %) 22 (27 %) 17 (17 %) 15 (14.85 %) 20 (18.18 %)
61+ 14 (14 %) 19 (17.80 %) 14 (14 %) 21 (21 %) 32 (31.68 %) 18 (16.36 %)
AU- Australia, CA- Canada, CNS- Central nervous system, ES- Spain, FR- France, JPN- Japan, UK- United Kingdom
*Figures rounded to 2 decimal places
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The lowest utility scores were recorded for the severe
generalised flare HS, rather than the severe renal flare
HS or severe CNS flare HS. Previously studies have re-
ported no significant difference in HRQoL between SLE
patients with and without renal involvement [9]. The
clinical severity of severe CNS and severe renal flares is
substantial; however clinical measures are based on
physiological or pathological measurements and may
have only little relationship to patients’ feeling of well-
being [11, 24, 14]. These findings are consistent with
insights from patient experiences gathered during HS de-
velopment, as the most bothersome symptoms during
flare reported by patients (e.g. joints, pain, fatigue) did not
always correlate with clinical severity. These findings
highlight the importance of including patient perspective/
patient-reported outcomes alongside clinical outcomes in
the development of new treatments for SLE.
Furthermore, these results are consistent with the exist-
ing literature. The severe generalised HS presented in this
study included more severe musculoskeletal, fatigue and
pain manifestations versus the severe renal flare HS and
severe CNS flare HS. Additionally, the severe generalised
HS description included more descriptive statements
highlighting the emotional impact of these manifestations
e.g. depression and anxiety associated with an inability to
carry out daily activities and the perception of being a
burden to family and friends. Previous reports suggest
that SLE patients experiencing high levels of pain were
also burdened with greater fatigue, anxiety and depression,
and as a result had a significantly lower HRQoL [12, 14].
Patient-reported fatigue has been shown to have a signifi-
cant impact on multiple aspects of an SLE patients’ life
(emotion, cognition, work, activities of daily living, social
activities etc.) [13, 14]. Increased treatment and subsequent
cumulative organ damage have been shown to be sig-
nificant predictors of lower HRQoL scores [25], and
treatment-related adverse events have been found to
have a negative impact on patient HRQoL in approxi-
mately 70 % of patients [26]. Increased medication and
hospital visits were included within the flare HS
Table 4 TTO utility scores for each health state across countries
Health state
Country Anchor Mild Moderate Severe generalised Severe CNS Severe renal
AU Mean 0.75 0.60 0.41 0.23 0.30 0.35
SD 0.20 0.26 0.30 0.24 0.26 0.27
Median 0.79 0.60 0.48 0.14 0.25 0.32
Min–Max 0.06–1.00 0.00–1.00* 0.00–1.00 0.00–0.93 0.00–0.90 0.00–1.00
CA Mean 0.76 0.65 0.42 0.28 0.35 0.37
SD 0.23 0.27 0.28 0.25 0.26 0.27
Median 0.80 0.70 0.43 0.19 0.34 0.32
Min–Max 0.00–1.00* 0.00–1.00* 0.00–1.00* 0.00–1.00* 0.00–1.00* 0.00–1.00*
ES Mean 0.80 0.71 0.53 0.33 0.45 0.43
SD 0.24 0.28 0.31 0.28 0.29 0.28
Median 0.90 0.79 0.53 0.30 0.45 0.42
Min–Max 0.00–1.00 0.00–1.00 0.00–1.00 0.00–0.93 0.00–0.99 0.00–0.99
FR Mean 0.80 0.64 0.46 0.26 0.34 0.33
SD 0.20 0.28 0.29 0.25 0.27 0.25
Median 0.80 0.70 0.50 0.20 0.30 0.35
Min–Max 0.00–1.00* 0.00–1.00 0.00–1.00 0.00–1.00 0.00–1.00 0.00–1.00
JPN Mean 0.66 0.55 0.38 0.19 0.33 0.36
SD 0.29 0.27 0.28 0.21 0.27 0.27
Median 0.71 0.56 0.40 0.10 0.30 0.35
Min–Max 0.00–1.00* 0.00–1.00* 0.00–0.95 0.00–0.95 0.00–0.95 0.00–1.00
UK Mean 0.82 0.71 0.48 0.29 0.36 0.45
SD 0.18 0.23 0.26 0.25 0.26 0.27
Median 0.88 0.74 0.50 0.25 0.33 0.44
Min–Max 0.01–1.00 0.01–1.00 0.00–1.00* 0.00–0.97* 0.00–1.00* 0.00–1.00*
AU- Australia, CA- Canada, CNS- Central nervous system, ES- Spain, FR- France, JPN-Japan, SD-Standard deviation, UK- United Kingdom
*Scores rounded to 2 decimal places, the minimum score recorded was 1 day (0 when rounded)
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descriptors. Further research to quantify the impact of
these factors on the general population’s valuation of
the HS descriptions is needed.
Within our study the lowest utility scores were often
observed in the Japanese cohort, with the exception of
the severe renal flare HS and the severe CNS flare HS.
Previous studies, not specific to SLE, have shown EQ-5D
derived utility scores vary on average by 0.24 between
Japan and the UK – this may be due to cultural dispar-
ities [27, 28]. Differences observed in utility scores may
be reflective of differences in social preference weights
between populations. These variations could be due to
the general population’s perception of disease severity
and impact [29]; descriptors within the HS may have
resonated more with the general population in Japan.
The TTO methodology is a standardised tool for HS
valuations by HealthTechnology Assessment (HTA) bodies
[18]. The six HS were developed using interviews with
physicians and patients as recommended by NICE; fur-
thermore the HS were validated by independent expert
rheumatologists from 5 different countries (AU, CA, ES,
FR, JPN) [18]. Previously large differences in elicited utility
values have been observed for the same HS when using
different interviewers, due to methodological inconsisten-
cies in the TTO exercise [30]. The utility scores elicited
within this study are consistent across six countries, sug-
gesting methodical limitations were minimal.
It is acknowledged, despite being a widely accepted
method, there are some limitations to the TTO tech-
nique. Some authors have raised doubts over willingness
to trade life for improved health and whether it reveals
true preferences [31]. Although not observed within this
study, ease of discussing trading off years has been iden-
tified as problematic particularly in religious or elderly
populations [18, 32]. In addition, this TTO method did
not allow for HS to be valued as worse than dead.
The HS may fail to capture all aspects of HRQoL
which may influence valuation by the general public
[33]. Descriptors within the HS may resonate differently
with members of the general public, therefore it is ac-
knowledged there may be a difference in the interpret-
ation of the HS. However, during the development of
the HS, pain and fatigue were both cited as the most
bothersome by the patients; this was also reflected in
some participants’ TTO scores whereby the moderate
HS was ranked as more severe than the severe CNS or
severe renal HS. The authors observed during the pa-
tient interviews that clinical severity may not correlate
with patients HRQoL. For example patients with severe
underlying disease activity i.e. severe renal flare, may
also experience mild skin and joint manifestations in
addition to some indicative symptoms of kidney involve-
ment such as headaches and swollen legs which were
often cited as less bothersome.
Due to the heterogeneous nature of SLE, not all organ
manifestations could be captured, therefore utility values
derived from this study may not be applicable to other
SLE manifestations of similar overall clinical severity. The
HS did not capture the length or frequency of flares, as this
is highly variable by patient, and the standard 10 year time-
frame for the TTO exercise did not reflect the variation in
actual survival between HS. SLE patients have previously
reported considerable uncertainty surrounding their condi-
tion in particular relating to the timing, severity and future
consequences of flare [34]. Uncertainty is closely related to
increased anxiety and a negative impact on patient HRQoL
[34]. Younger age is a significant predictor of uncertainty
and subsequently of a lower HRQoL for SLE patients, as
SLE may affect career development, fertility and ability to
raise a family; these consequences have not been explored
within this study [34]. Furthermore, a large SLE cohort
study demonstrated that over the course of one year pa-
tients were more likely to experience periods of persistently
active disease (PAD) than a flare episode [22]. The reported
frequency of PAD compared to flare warrants further in-
vestigation into the disutility associated with PAD.
Utility values have been derived from the general
population, in line with HTA guidance, rather than from
patients with SLE. To ensure a demographic representa-
tion of society a 50:50, female to male ratio was used for
utility elicitation, therefore gender neutral HS were devel-
oped. SLE predominantly affects females, 90:10 female to
male ratio, as such health state development was guided
by only female SLE patients. Further analyses by gender
may elucidate any differences in perception of the HS by
male and female members of the general public.
As a representative sample of the general population was
recruited, the distribution of participants’ age differs from
that of a typical SLE population. Age has previously been
found to have an impact on valuation of HS by the general
public [18]. Within the utility elicitation participants must
imagine they are a 41 year old SLE patient; however, it is
acknowledged that participants will draw upon their own
experiences and descriptors within the HS may resonate
differently with members of the general public. Own health
has also been found to have an impact on valuation of HS
[18], although in our sample mean VAS scores for own
health were higher than the anchor HS in all countries
[35]. Age and own health may be a contributing factor for
any differences in perception and willingness to trade.
Despite these limitations this study shows that from a
societal perspective increasing severity of flare is associ-
ated with a decrease in utility scores. The impact of flare
on HRQoL, particularly of certain organ manifestations
(e.g. musculoskeletal) is consistent with results reported in
the literature. These results can be applied in future cost-
utility analyses of healthcare interventions which aim to
reduce the frequency and or severity of flares in SLE.
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